Fiduciary Financial Services of The Southwest Inc. TX Acquires 846 Shares of Eli Lilly And Co (NYSE:LLY)

Fiduciary Financial Services of The Southwest Inc. TX raised its holdings in Eli Lilly And Co (NYSE:LLY) by 7.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,218 shares of the company’s stock after buying an additional 846 shares during the quarter. Fiduciary Financial Services of The Southwest Inc. TX’s holdings in Eli Lilly And Co were worth $1,366,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of LLY. Nuveen Asset Management LLC boosted its position in shares of Eli Lilly And Co by 20,030.9% during the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after purchasing an additional 7,229,751 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Eli Lilly And Co by 218.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock worth $255,770,000 after purchasing an additional 1,583,947 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC boosted its position in shares of Eli Lilly And Co by 5,612.3% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,591,396 shares of the company’s stock worth $176,311,000 after purchasing an additional 1,563,537 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Eli Lilly And Co by 53.3% in the 2nd quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock worth $480,048,000 after purchasing an additional 1,507,050 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Eli Lilly And Co by 1.5% in the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after purchasing an additional 898,845 shares in the last quarter. Hedge funds and other institutional investors own 76.75% of the company’s stock.

A number of analysts have recently weighed in on the company. Bank of America assumed coverage on Eli Lilly And Co in a research report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. UBS Group lowered their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Finally, ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $128.31.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,500 shares of Eli Lilly And Co stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the transaction, the senior vice president now owns 33,806 shares in the company, valued at approximately $3,955,302. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. Insiders sold a total of 243,452 shares of company stock valued at $28,252,925 in the last 90 days. 0.11% of the stock is currently owned by company insiders.

LLY stock traded down $0.29 during midday trading on Thursday, reaching $107.11. The stock had a trading volume of 126,327 shares, compared to its average volume of 2,709,977. The stock has a market cap of $106.04 billion, a PE ratio of 19.30, a P/E/G ratio of 1.87 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13. The firm has a fifty day simple moving average of $110.73 and a two-hundred day simple moving average of $113.52. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.43 by $0.05. The company had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $1.39 EPS. On average, sell-side analysts predict that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.645 dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.41%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Monthly Dividend Stocks Can Provide Solid Income

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.